ResearcherFred Hutch Cancer CenterActive in the last 2 years
Sita Kugel
Matched on ORCID iD 0000-0001-7202-187X; OpenAlex author ID A5034075190; NIH RePORTER profile ID 11787688. Sources: funder_awards.
Their work
- Papers
- 9 (first author 0, last author 4)
- Trials
- 0
- Grants
- 4
- Labs led
- 2
- Collaborators
- 43
2016: 1 paper, 1 grant · 2017: none · 2018: none · 2019: 1 grant · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 3 papers, 1 grant · 2026: 5 papers, 1 grant
Papers 9
- ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer. Last author DOI 10.1038/s41467-026-73380-x↗
- MondoA mediates transcriptional coordination between the MYC network and the integrated stress response in pancreatic cancer. Co-author DOI 10.1073/pnas.2524659123↗
- Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag091↗
- Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinom… Co-author DOI 10.3390/cancers18030507↗
- HMGA2 Expression in Pancreatic Ductal Adenocarcinoma Controls Tumor Microenvironment and Immunosuppression via IL1α Last author DOI 10.64898/2026.10.02.754697↗
- Long-Term Survival Following Chemoradiation in Locoregional Recurrent Germline ATM Mutated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.adro.2025.101742↗
- HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity. Last author DOI 10.1038/s41467-025-60129-1↗
- HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-24-2200↗
- SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Co-author DOI 10.1016/j.cell.2016.04.033↗
Grants 4
- Unraveling the role of LIN28B/HMGA2 axis in pancreatic cancer lineage plasticity AWARD pancan:2026-sita-kugel-phd-unraveling-the-role-of-lin28b-hmga2-axis
- Exploring the epigenetic control of pancreatic cancer subtypes R37CA241472↗
- Deciphering the role of Lin28b in pancreatic cancer to guide therapeutic discovery R00CA208032↗
- Deciphering the role of Lin28b in pancreatic cancer to guide therapeutic discovery K99CA208032↗
Closest collaborators
The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Stephanie Dobersch · 5 shared papers, 2025–2026 · strength 1.15
- Paper MondoA mediates transcriptional coordination between the MYC network and the integrated stress response in pancreatic c… DOI 10.1073/pnas.2524659123↗
- Paper ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer. DOI 10.1038/s41467-026-73380-x↗
- Paper HMGA2 Expression in Pancreatic Ductal Adenocarcinoma Controls Tumor Microenvironment and Immunosuppression via IL1α DOI 10.64898/2026.10.02.754697↗
- Naomi Yamamoto · 5 shared papers, 2025–2026 · strength 1.09
- Paper Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastati… DOI 10.1093/oncolo/oyag091↗
- Paper ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer. DOI 10.1038/s41467-026-73380-x↗
- Paper HMGA2 Expression in Pancreatic Ductal Adenocarcinoma Controls Tumor Microenvironment and Immunosuppression via IL1α DOI 10.64898/2026.10.02.754697↗
- Rachael Ann Safyan · 4 shared papers, 2025–2026 · strength 0.92
- Paper Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastati… DOI 10.1093/oncolo/oyag091↗
- Paper Long-Term Survival Following Chemoradiation in Locoregional Recurrent Germline ATM Mutated Pancreatic Ductal Adenocarci… DOI 10.1016/j.adro.2025.101742↗
- Paper Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Me… DOI 10.3390/cancers18030507↗
- Faiyaz Notta · 4 shared papers, 2025–2026 · strength 0.83
- Paper ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer. DOI 10.1038/s41467-026-73380-x↗
- Paper HMGA2 Expression in Pancreatic Ductal Adenocarcinoma Controls Tumor Microenvironment and Immunosuppression via IL1α DOI 10.64898/2026.10.02.754697↗
- Paper HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity. DOI 10.1038/s41467-025-60129-1↗
- Elena Gabriela Chiorean · 3 shared papers, 2025–2026 · strength 0.66
- Paper Long-Term Survival Following Chemoradiation in Locoregional Recurrent Germline ATM Mutated Pancreatic Ductal Adenocarci… DOI 10.1016/j.adro.2025.101742↗
- Paper Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Me… DOI 10.3390/cancers18030507↗
- Paper HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-24-2200↗
- Sunil R. Hingorani · 3 shared papers, 2025–2026 · strength 0.64
- Paper Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Me… DOI 10.3390/cancers18030507↗
- Paper HMGA2 Expression in Pancreatic Ductal Adenocarcinoma Controls Tumor Microenvironment and Immunosuppression via IL1α DOI 10.64898/2026.10.02.754697↗
- Paper HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-24-2200↗
- Adrianne Wallace-Povirk · 2 shared papers, 2026 · strength 0.45
- Paper ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer. DOI 10.1038/s41467-026-73380-x↗
- Paper HMGA2 Expression in Pancreatic Ductal Adenocarcinoma Controls Tumor Microenvironment and Immunosuppression via IL1α DOI 10.64898/2026.10.02.754697↗
- Nina G. Steele · 2 shared papers, 2025–2026 · strength 0.41
- Ian M. Loveless · 2 shared papers, 2025–2026 · strength 0.41
- Howard C. Crawford · 2 shared papers, 2025–2026 · strength 0.41
- Patrick A. Carroll · 1 shared paper, 2026 · strength 0.32
- Erin L. Ramsey · 1 shared paper, 2026 · strength 0.32
- Susan Elaine Bates · 1 shared paper, 2026 · strength 0.26
- Ruth Aroon White · 1 shared paper, 2026 · strength 0.26
- Jacob K.R. Jamison · 1 shared paper, 2026 · strength 0.26
- Tamas A. Gonda · 1 shared paper, 2026 · strength 0.26
- Gulam Abbas Manji · 1 shared paper, 2026 · strength 0.26
- Paul E. Oberstein · 1 shared paper, 2026 · strength 0.26
- Venu Gopal Pillarisetty · 1 shared paper, 2025 · strength 0.24
- Jonathan G. Sham · 1 shared paper, 2025 · strength 0.24
- Dushyant V. Sahani · 1 shared paper, 2025 · strength 0.24
- Martin C. Whittle · 1 shared paper, 2026 · strength 0.23
- Sabrina Ge · 1 shared paper, 2026 · strength 0.23
- Jessica E. Gianopulos · 1 shared paper, 2026 · strength 0.23
- Andrew Eugene Hendifar · 1 shared paper, 2026 · strength 0.23
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.